Table 3 Multivariable logistic regression analyses for TNFi-insensitivity and poor response to a TNFi

Gender

Female

1 (reference)

1 (reference)

Male

0.99

0.57–1.71

0.97

0.77

0.58–1.03

0.08

Age category

≦ 50

1 (reference)

1 (reference)

51–60

1.27

0.69–2.34

0.44

1.35

0.97–1.86

0.07

61–70

0.68

0.35–1.32

0.25

1.14

0.82–1.58

0.43

≧ 71

0.79

0.40–1.55

0.49

1.04

0.74–1.47

0.83

Duration (year)

< 0.5

1 (reference)

1 (reference)

0.5–2

0.87

0.47–1.59

0.65

1.24

0.87–1.76

0.24

2–5

0.75

0.37–1.53

0.43

1.27

0.86–1.89

0.23

≥ 5

0.51

0.26–1.01

0.05^†

1.16

0.81–1.66

0.43

DAS28-CRP

< 2.6

1 (reference)

1 (reference)

2.6–4.1

0.52

0.10–2.61

0.42

3.71

0.83–16.53

0.09

> 4.1

1.46

0.31–6.79

0.63

6.93

1.57–30.48

0.01^†

0.99

0.60–1.63

0.97

1.08

0.83–1.41

0.58

1.71

1.02–2.87

0.04^†

1.29

1.00–1.67

0.05^†

Dose of MTX (mg/week)

0

1 (reference)

1 (reference)

1–6

1.22

0.45–3.30

0.70

0.86

0.52–1.45

0.58

7–9

0.88

0.37–2.06

0.76

1.04

0.67–1.60

0.87

10–15

0.87

0.38–1.97

0.73

0.93

0.60–1.43

0.73

> 15

0.60

0.24–1.46

0.26

0.69

0.43–1.11

0.13

0.67

0.42–1.07

0.09

0.86

0.68–1.08

0.20

Biologics

IFX

1 (reference)

1 (reference)

ETA

1.63

0.77–3.44

0.20

1.19

0.84–1.69

0.33

ADA

1.03

0.53–2.00

0.94

0.59

0.43–0.83

< 0.01^†

GLM

2.19

0.42–11.40

0.35

1.95

0.80–4.77

0.14

CZP

2.64

1.32–5.28

0.01^†

0.64

0.41–0.98

0.04^†

Phase

I + II

1 (reference)

1 (reference)

III

1.30

0.71–2.38

0.39

0.65

0.49–0.88

0.01^†